Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma.

Fan QW, Cheng CK, Gustafson WC, Charron E, Zipper P, Wong RA, Chen J, Lau J, Knobbe-Thomsen C, Weller M, Jura N, Reifenberger G, Shokat KM, Weiss WA.

Cancer Cell. 2013 Oct 14;24(4):438-49. doi: 10.1016/j.ccr.2013.09.004.

2.

EGFR and EGFRvIII in glioblastoma: partners in crime.

Zadeh G, Bhat KP, Aldape K.

Cancer Cell. 2013 Oct 14;24(4):403-4. doi: 10.1016/j.ccr.2013.09.017.

3.

Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes.

Lo HW, Cao X, Zhu H, Ali-Osman F.

Mol Cancer Res. 2010 Feb;8(2):232-45. doi: 10.1158/1541-7786.MCR-09-0391. Epub 2010 Feb 9.

4.

Control of glioblastoma tumorigenesis by feed-forward cytokine signaling.

Jahani-Asl A, Yin H, Soleimani VD, Haque T, Luchman HA, Chang NC, Sincennes MC, Puram SV, Scott AM, Lorimer IA, Perkins TJ, Ligon KL, Weiss S, Rudnicki MA, Bonni A.

Nat Neurosci. 2016 Jun;19(6):798-806. doi: 10.1038/nn.4295. Epub 2016 Apr 25.

5.

JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma.

Zheng Q, Han L, Dong Y, Tian J, Huang W, Liu Z, Jia X, Jiang T, Zhang J, Li X, Kang C, Ren H.

Neuro Oncol. 2014 Sep;16(9):1229-43. doi: 10.1093/neuonc/nou046. Epub 2014 May 25.

6.

Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.

Ramnarain DB, Park S, Lee DY, Hatanpaa KJ, Scoggin SO, Otu H, Libermann TA, Raisanen JM, Ashfaq R, Wong ET, Wu J, Elliott R, Habib AA.

Cancer Res. 2006 Jan 15;66(2):867-74.

7.

Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway.

de la Iglesia N, Konopka G, Puram SV, Chan JA, Bachoo RM, You MJ, Levy DE, Depinho RA, Bonni A.

Genes Dev. 2008 Feb 15;22(4):449-62. doi: 10.1101/gad.1606508. Epub 2008 Feb 7.

9.

EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma.

Li L, Puliyappadamba VT, Chakraborty S, Rehman A, Vemireddy V, Saha D, Souza RF, Hatanpaa KJ, Koduru P, Burma S, Boothman DA, Habib AA.

Oncogene. 2015 Jan 2;34(1):129-134. doi: 10.1038/onc.2013.534. Epub 2013 Dec 23.

10.

An EGFR wild type-EGFRvIII-HB-EGF feed-forward loop regulates the activation of EGFRvIII.

Li L, Chakraborty S, Yang CR, Hatanpaa KJ, Cipher DJ, Puliyappadamba VT, Rehman A, Jiwani AJ, Mickey B, Madden C, Raisanen J, Burma S, Saha D, Wang Z, Pingle SC, Kesari S, Boothman DA, Habib AA.

Oncogene. 2014 Aug 14;33(33):4253-64. doi: 10.1038/onc.2013.400. Epub 2013 Sep 30.

11.

Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.

Johnson H, Del Rosario AM, Bryson BD, Schroeder MA, Sarkaria JN, White FM.

Mol Cell Proteomics. 2012 Dec;11(12):1724-40. doi: 10.1074/mcp.M112.019984. Epub 2012 Sep 10.

12.

Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter.

Latha K, Li M, Chumbalkar V, Gururaj A, Hwang Y, Dakeng S, Sawaya R, Aldape K, Cavenee WK, Bogler O, Furnari FB.

Int J Cancer. 2013 Feb 1;132(3):509-20. doi: 10.1002/ijc.27690. Epub 2012 Jul 9. Erratum in: Int J Cancer. 2015 Sep 15;137(6):E10-1.

13.

STAT1 gene expression is enhanced by nuclear EGFR and HER2 via cooperation with STAT3.

Han W, Carpenter RL, Cao X, Lo HW.

Mol Carcinog. 2013 Dec;52(12):959-69. doi: 10.1002/mc.21936. Epub 2012 Jun 12.

14.

Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.

Hu J, Jo M, Cavenee WK, Furnari F, VandenBerg SR, Gonias SL.

Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):15984-9. doi: 10.1073/pnas.1113416108. Epub 2011 Sep 6.

15.

Selective coexpression of VEGF receptor 2 in EGFRvIII-positive glioblastoma cells prevents cellular senescence and contributes to their aggressive nature.

Jones KA, Gilder AS, Lam MS, Du N, Banki MA, Merati A, Pizzo DP, VandenBerg SR, Gonias SL.

Neuro Oncol. 2016 May;18(5):667-78. doi: 10.1093/neuonc/nov243. Epub 2015 Sep 29.

16.

Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.

Learn CA, Hartzell TL, Wikstrand CJ, Archer GE, Rich JN, Friedman AH, Friedman HS, Bigner DD, Sampson JH.

Clin Cancer Res. 2004 May 1;10(9):3216-24.

17.

RRAD promotes EGFR-mediated STAT3 activation and induces temozolomide resistance of malignant glioblastoma.

Yeom SY, Nam DH, Park C.

Mol Cancer Ther. 2014 Dec;13(12):3049-61. doi: 10.1158/1535-7163.MCT-14-0244. Epub 2014 Oct 13.

18.

IGFBP2 potentiates nuclear EGFR-STAT3 signaling.

Chua CY, Liu Y, Granberg KJ, Hu L, Haapasalo H, Annala MJ, Cogdell DE, Verploegen M, Moore LM, Fuller GN, Nykter M, Cavenee WK, Zhang W.

Oncogene. 2016 Feb 11;35(6):738-47. doi: 10.1038/onc.2015.131. Epub 2015 Apr 20.

19.

Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion.

Gilder AS, Jones KA, Hu J, Wang L, Chen CC, Carter BS, Gonias SL.

J Biol Chem. 2015 Jun 12;290(24):14798-809. doi: 10.1074/jbc.M115.637488. Epub 2015 Apr 2.

20.

Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis.

Feng H, Hu B, Jarzynka MJ, Li Y, Keezer S, Johns TG, Tang CK, Hamilton RL, Vuori K, Nishikawa R, Sarkaria JN, Fenton T, Cheng T, Furnari FB, Cavenee WK, Cheng SY.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3018-23. doi: 10.1073/pnas.1121457109. Epub 2012 Feb 7.

Supplemental Content

Support Center